Revelation Biosciences, Inc. (REVB) News
Follow Revelation Biosciences, Inc. (REVB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Revolution Beauty Group expects H1 FY27 adjusted EBITDA
Revolution Beauty Group PLC said it expects to report first-half FY27 adjusted EBITDA of not less than £2 mln.
EARNINGS | Sep 17, 2026, 06:42 AM UTC
L
Revelation Biosciences selects Avance Clinical as CRO for Titan Phase 2/3
Revelation Biosciences (REVB) selects Avance Clinical as CRO for its Phase 2/3 Titan study, which is expected to begin later this year.
EQUITY | Aug 19, 2026, 01:05 PM UTC
L
Revelation Biosciences hires Avance Clinical as CRO for TITAN Phase 2/3
Revelation Biosciences (REVB) selects Avance Clinical as the CRO for its Phase 2/3 TITAN study.
EQUITY | Aug 19, 2026, 01:04 PM UTC
L
REVB - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
REVB - Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
EQUITY | Aug 03, 2026, 01:00 PM UTC